Measurement of FGF21 as a biomarker of fructose metabolism
US10132816B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2014 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | May 29, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/04
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides, inter alia, methods of monitoring the fructose response of a subject by determining the level of fibroblast growth factor 21 (FGF21) gene expression product in a biological sample (such as a serum sample) from the subject, where the subject was previously administered a fructose bolus. The invention also provides methods of monitoring the response of a subject to a treatment for a disorder of metabolism, for discriminating fructose intolerance from other gastrointestinal disorders not associated with fructose intolerance, for identifying a subject at risk for developing a disorder of metabolism, as well as methods of treatment for a disorder of metabolism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.